AJMC January 10, 2025
Cameron Santoro

Key Takeaways

  • The US pharmaceutical market is the largest globally, with high drug spending and profitability, influenced by market competition rather than government pricing controls.
  • The 340B program’s effectiveness is questioned, with states enacting laws to ensure discounted drug sales to contract pharmacies, amid unclear financial benefits for patient care.
  • Legal actions against PBMs target anticompetitive practices, aiming to reduce drug prices and improve transparency, prompting a shift towards more transparent PBM models.
  • Biosimilars and transparent pricing models, like Mark Cuban’s Cost Plus Drug Company, are disrupting traditional drug pricing, enhancing affordability and accessibility for patients.

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future of drug access...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Pharma, Pharma / Biotech
Related Articles:
Digital Retail Platforms: The new concept of Pharma to sell directly to patients
Boosting biopharma R&D performance with a next-generation technology stack
Charting the path to patients
External innovation: Biopharma dealmaking to boost R&D productivity
Building a shared vision for pharma R&D–supplier partnerships

Share This Article